Silence Therapeutics plc (SLN)
Silence Therapeutics plc at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Silence Therapeutics plc (SLN) is a Biotechnology company based in GB with a market capitalization of $512.5M. Revenue declined 98.7% year-over-year and free cash flow was negative at -$62.3M. This page tracks SLN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
GB · 116 employees · IPO Sep 8, 2020
Valuation
Valuation & price
$6.10as of May 17, 2026· -44.4% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
8.23
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$512.5M
Market cap
-98.7%
Revenue growth (YoY)
61.5%
Gross margin
-$62.3M
Free cash flow (USD)
-$85M
Net debt
Net cash position
206.4%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 16, 2026Filing
Executive Separation Agreement
- 8-K eventJun 23, 2026Filing
Corporate Presentation Update
- 8-K eventJun 16, 2026Filing
Annual General Meeting Results
- 8-K eventJun 11, 2026Filing
Clinical Data Presentation
- FinancingMay 18, 2026Filing
Securities Registration
- 8-K eventMay 18, 2026Filing
Sales Agreement Established
- 8-K eventMay 7, 2026Filing
Earnings Release
- Quarterly reportMay 7, 2026Filing
10-Q Filed
Questions
Frequently asked questions
What is Silence Therapeutics plc's market cap?
Silence Therapeutics plc (SLN) has a market capitalization of $512.5M.
What is SLN's P/E ratio?
A meaningful P/E ratio is not available for SLN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is SLN's price-to-book (P/B) ratio?
SLN trades at 8.23 times book value per share.
Are insiders buying SLN stock?
SEC Form 4 filings show no open-market insider buys at Silence Therapeutics plc in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.